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ABSTRACT 
Cardiovascular disease is the leading cause of death and morbidity in the world. Myocardial 
infarction and stroke constitute the main manifestations of atherosclerosis that lead to the 
majority of cardiovascular events. Calcific aortic valve stenosis is the most common valve 
pathology. Atherosclerosis and aortic valve stenosis share common risk factors such as 
hypercholesterolemia. Lipid lowering treatment has ameliorated the incidence of fatal events; 
however, residual risk remains indicating the need to address the inflammatory component in 
cardiovascular disease.  
Many inflammatory mediators, such as cytokines and receptors have been implicated to play 
important role in the pathogenesis and the endpoints caused by an atherosclerotic plaque 
rupture. The role of pattern recognition receptors has been highlighted in several experimental 
studies. Both protective and detrimental effects have been described for the members of Toll-
like receptor (TLR) family, a class of pattern recognition receptors. Several studies have 
focused on the role of the cell surface TLRs. The aim of the current thesis is to investigate the 
role of the intracellular pattern recognition receptor, TLR7. To gain information of the 
pathophysiological mechanisms that TLR7 is involved, both human cohorts of atherosclerosis 
and aortic valve stenosis as well as experimental models of atherosclerosis have been utilized.  
In Paper I, mRNA expression of TLR7 in human carotid plaques was associated with patients´ 
outcome. Patients that expressed higher levels of TLR7 in their removed plaque had fewer 
future adverse cardio- and cerebrovascular events. Macrophages and T cells were co-localized 
with TLR7 in carotid plaques. Furthermore, carotid plaque tissue responded with increased 
cytokine secretion upon ex vivo stimulation with a synthetic TLR7 ligand.      
Paper II showed TLR7 mRNA expression in calcified aortic valves. TLR7 mRNA was 
increased in calcified areas of the aortic valves compare to intermediate and healthy areas. In 
addition, TLR7 expression was associated with M2 macrophage markers in all parts of the 
aortic valve. Stimulation of calcified aortic valves ex vivo with a synthetic TLR7 ligand elicited 
cytokine response that was possibly derived directly or indirectly by macrophages.  
In Paper III, we investigated the in vivo effects of a synthetic TLR7 ligand in experimental 
atherosclerosis. Locally, treatment with the synthetic TLR7 ligand led to decrease in lesion size 
and changes in plaque composition. The lesions of the treated mice presented lesions with 
smaller necrotic core and fewer apoptotic cells compare to the control. The treatment had effect 
in the spleen, leading to marginal zone B and regulatory T cell expansion. In the plasma, we 
observed decrease in cholesterol levels and increase in IgM antibodies against oxidized low-
density lipoprotein.  
The three studies presented in this thesis illustrate the protective role of TLR7 in atherosclerosis 
and aortic valve stenosis. TLR7 was expressed in both myeloid cells and lymphocytes 
indicating a role of the receptor in bridging innate and adaptive immune. The current results 
can encourage the investigation of TLR7 ligands as therapeutic intervention in cardiovascular 
disease.     
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1 INTRODUCTION 
1.1 CARDIOVASCULAR DISEASE BURDEN 
Cardiovascular diseases (CVD) are the leading cause of death worldwide [1]. One third of 
mortality in the world is due to cardiovascular disease endpoints. Between 1990 and 2015, 
approximately a 5 million increase in cardiovascular deaths occurred worldwide [2]. The 
prevalence of cardiovascular disease is associated with the sociodemographic status of the 
population. Increase in the sociodemographic status resulted in decrease in the number of 
deaths in a course of 25 years. However, this decrease seems to have reached a plateau. 
Ischemic heart disease is the first cardiovascular disease responsible for premature death and 
morbidity in the population [2]. In addition, morbidity caused by CVD has great impact in the 
economic costs for the healthcare system. 
Most cardiovascular events are a result of the manifestations of atherosclerosis, such as 
ischemic heart disease and ischemic stroke. Collectively these manifestations are classified as 
major adverse cardio- and cerebrovascular events (MACCE). MACCE is defined as the 
incidence of myocardial infarction (MI), stroke, coronary and peripheral artery interventions 
[3, 4]. The main risk factors for developing atherosclerosis are established, including 
hypercholesterolemia, hypertension, smoking and obesity [5]. Aortic valve stenosis (AVS) is 
another cardiovascular disease that shares common risk factors with atherosclerosis with high 
prevalence in the population. AVS is ranked third in the most-common cardiovascular diseases 
in the developed countries [6]. The prevalence of the disease increases by age with 25% in 
individuals >65 years old.   
Lipid lowering drugs have successfully reduced atherosclerotic disease mortality. However, 
70% of the events are still not prevented [7]. Regarding AVS the only therapeutical approach 
is surgical or transcutaneous valve replacement. There is no pharmacological treatment that 
reduces the progression of AVS and in contrast to atherosclerosis, statins have no effect on the 
clinical outcome of the disease [8]. Taken together, the above indicate the emerging need for 
developing new therapeutic approach combined with the established. 
1.2 INFLAMMATION AND CARDIOVASCULAR DISEASE  
Early evidence for the causative factor for atherosclerosis development was generated by the 
experimental studies of Anitschkow and Chalatow [9]. They have showed that rabbits fed a 
high cholesterol diet formed fatty streaks. For several decades, the pathogenesis of 
atherosclerosis was attributed to cholesterol infiltration in the vessel wall, accumulation and 
eventually formation of lesions. However, lipid loaded foam cells were later identified in the 
lesions of rabbits fed with high cholesterol diet. These cells were having characteristics similar 
to macrophages [10]. Furthermore, Jonasson and Hansson demonstrated infiltration of other 
immune cells in atherosclerotic lesions [11-13]. Specifically, T cells and 
monocytes/macrophages were detected both in early stage fibrous plaques and in advanced 
lesions. Macrophages and smooth muscle cells expressed major histocompatibility complex 
 2 
(MHC) II cell surface receptor (HLA-DR) indicating ongoing antigen presentation to T cells 
starting at early stage in the lesions [12]. That finding indicated involvement of immune system 
in the pathogenesis and progression of atherosclerosis [5].  
More evidence was added later to the inflammatory hypothesis as a pathogenic factor in 
atherosclerosis by clinical studies and trials. High levels of C-reactive protein (CRP) was 
shown to be elevated in patients with stable angina and myocardial infarction that had a history 
of stable angina. This study indicated that the elevation in CRP was prior to myocardial 
infarction and thus was not attributed to myocardial necrosis [14]. Although, there was an 
increasing body of evidence regarding the involvement of the immune system in 
atherosclerosis, the inflammatory hypothesis was validated in 2017 with the results of the 
CANTOS trial. In CANTOS trial, patients with prior myocardial infarction and high CRP 
levels were treated with canakinumab, an interleukin (IL)-1β inhibitor. At the end of the 
treatment, the patients that received canakinumab presented lower levels of CRP compared to 
baseline and fewer future cardiovascular events compared to the placebo group. The decrease 
in CRP levels and reoccurring cardiovascular events was independent of cholesterol levels, 
which remained unchanged, showing the importance of immune contribution in the 
pathogenesis of cardiovascular disease [15].  
1.3 CHOLESTEROL METABOLISM    
Cholesterol is an established cause of cardiovascular disease. Familial hypercholesterolemia 
(FH) is an autosomal dominant disorder. Patients with FH present elevated blood cholesterol 
levels and cardiovascular symptoms from the third decade of life. Homozygous individuals 
have up to six-fold increase of cholesterol levels that lead to atherosclerotic plaque formation 
during childhood and often to fatal cardiovascular event before the age of thirty [16]. The 
studies of Goldstein and Brown revealed that FH disorder was the result of mutations involved 
in cholesterol metabolism. They discovered that low-density lipoprotein (LDL), where most of 
blood cholesterol is found, enters the cells through binding to a specific receptor called LDL 
receptor (LDLR) in cultured human cells from healthy donors and FH patients. FH patients had 
decreased number of LDLR, which were totally absent in homozygous individuals [17]. For 
their discoveries in the regulation of cholesterol metabolism and the underlying mechanisms 
causing FH Goldstein and Brown were awarded the Nobel Prize in Physiology or Medicine in 
1985 [18].   
Cholesterol is a crucial component of the cell membranes that is available by diet and de novo 
biosynthesis in the body.  Furthermore, the synthesis of vitamin D, steroid hormones and bile 
salts require cholesterol as a precursor. The cholesterol that is absorbed by the intestine derives 
from diet and enters the intestine in bile. Approximately, half of the total amount of cholesterol 
is absorbed in the intestine while the rest is excreted in feces, bile salts and sebum [19].  
The liver plays central role in the biosynthesis and the distribution of cholesterol around the 
body. Enterocytes in the gut are assembling cholesterol and triglycerides with ApoB48 into 
chylomicrons [20]. Subsequently, chylomicrons transfer to the blood stream through the 
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lymphatic system.  In the circulation, the triglycerides of the chylomicrons are hydrolyzed by 
lipoprotein lipase that is located in the vascular endothelium. This process generates cholesterol 
rich chylomicrons of reduced size. Monocytes, adipocytes or the liver take up the fatty acids 
that are released from the chylomicrons. Similarly, the cholesterol rich chylomicron remnants 
are removed from the circulation from the liver by binding to both heparin sulphate and LDL 
receptor-like protein (LRP).  
Cholesterol is exported from the liver to the tissues in very low-density lipoprotein (VLDL). 
VLDL export by the liver involves the packaging of triglyceride with Apo B100 in the 
endoplasmic reticulum. The newly synthesized VLDL is assembled together with unesterified 
cholesterol and triglycerides into secretory vesicles in the Golgi. In pathological conditions 
such as obesity and insulin resistance, VLDL is overloaded with triglycerides. VLDL is 
removed in the liver by the LDLR, heparan sulphate (HSPGs), LDLR-related protein 1 (LRP1) 
and scavenger receptor B1 (SR-B1) [21, 22]. In the presence of cholesteryl ester transfer protein 
(CETP) cholesteryl ester from high-density lipoprotein (HDL) and LDL is transferred to 
VLDL. Esterification of cholesterol by cholesterol acyl transferase (LCAT) allows the 
accommodation of larger amounts of cholesterol into the lipoprotein core.  
Triglyceride removal from VLDL by lipoprotein lipase leads to formation of LDL. LDL can 
due to its small size cross the vascular endothelium and supply tissues with cholesterol. Excess 
of cholesterol arriving at the tissues in LDL is reversely transported back to the liver via HDL 
or the ATP Binding Cassette Subfamily A Member 1 (ABCA1) receptors of extrahepatic 
tissues. In the liver LDL is removed by LDL receptors or enters hepatocytes after leaving HDL 
[19].    
1.4 TOOLS FOR STUDYING CARDIOVASCULAR DISEASE 
Different approaches and methodologies have been developed in order to uncover the 
pathogenesis of human disease, to identify biomarkers for improved diagnosis methods and to 
provide therapeutic approaches. Important tools to achieve the above are the combination of in 
vitro cultures, mouse model and studies of human material either population based or through 
molecular analysis.  
1.4.1 Biobanks  
Biobanks are organized repositories of biological samples, responsible for appropriate long-
term storage of samples combined with several clinical and epidemiological patient data [23]. 
Biobanks follow standardized operating protocols that facilitate the comparability between 
samples in the same biobank and between biobanks worldwide. Usually, biobanks are built 
based on a disease-oriented model and are connected to a specific study. Biobank samples and 
data can provide several advantages such as better disease stratification, development of 
personalized medicine and establishment of worldwide health policies [24].   
Today functional genomic studies use large-scale analysis to get information from gene to RNA 
to protein on pathological processes. Blood samples that are easy to collect can be used in large 
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cohorts of patients for the identification of genetic markers and other parameters [25]. Genetic 
predisposition for certain diseases have been investigated through genome-wide association 
studies (GWAS). Several GWAS have associated single nucleotide polymorphisms (SNPs) to 
disease outcomes such as myocardial infarction [26, 27]. Furthermore, polymorphisms in a 
regulator gene of MHC II expression was correlated with autoimmune diseases and myocardial 
infarction [28].   
A blood sample cannot provide detailed information regarding the ongoing disease processes 
in the affected tissue. Valuable information is obtained regarding pathogenic or protective 
processes by the analysis of the infected tissue. Expression and regulation of genes can be 
affected not only by genetic factors but also by the microenvironment of the lesions in a specific 
disease. Transcript profiling provided the possibility to analyze mRNA from 20 000 genes in 
one sample and get information about the activation state of the genes in each sample. 
Nowadays, microarrays and sequencing provide information about the transcript profile of 
tissues or cells of interest in a specific disease.  
1.4.2 Animal models  
Several animal models are used for the study of atherosclerosis and aortic valve stenosis such 
as hypercholisterolaemic mice, pigs, rabbits and more seldom non-human primates. Mouse is 
the most favorable experimental animal for the study of cardiovascular diseases [29, 30].  The 
advantages of the use of mice in research include the relatively small cost, ease in breeding and 
genetic manipulation and short life cycle.  
Apolipoprotein E-deficient mice (Apoe-/-) [31, 32] and LDL-receptor-deficient mice (Ldlr-/-) 
[33] are the most commonly used animal models in atherosclerotic research [34-37]. Apoe-/- 
mice lack apoE, an apolipoprotein necessary for the removal of lipoprotein particles in 
circulation. In addition, the mice present high levels of plasma cholesterol and develop 
atherosclerosis spontaneously. Importantly, in Apoe-/- mice plasma cholesterol is located 
mainly in VLDL, chylomicrons and intermediate-density lipoprotein (IDL) particles. The 
atherosclerotic lesions develop particularly in the aortic branch and in branch points throughout 
the aorta. The lesions have similar morphology to the human plaques with presentation of all 
stages of plaque development, fatty streak, fibrous plaque and advanced lesions. In contrast to 
Apoe-/- mice that develop spontaneously atherosclerotic lesions, Ldlr-/- mice require high fat 
diet (HFD). Another difference between Apoe-/- and Ldlr-/- mice is that in Ldlr-/- mice plasma 
cholesterol is mainly located in the IDL and LDL fractions. Ldlr-/- mice on a high fat, high-
cholesterol diet have increased plasma cholesterol levels and develop lesions that resemble 
fatty streaks. HFD can also be used to accelerate atherogenesis in Apoe-/-. 
Nowadays, several methodologies have been developed that allow in depth study of the 
different processes from the initiation of atherosclerosis to advanced lesions. Genetic 
manipulation including generation of transgenic animals, temporal and conditional gene 
knockout and knock-in provided the opportunity to manipulate either the level or function of 
specific immune component. These genetic manipulations were of major importance in 
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dissecting the cellular and molecular mechanisms of the role of the immune system on 
cardiovascular diseases [29].  Furthermore, the study of the initiation of atherosclerosis has 
been possible by the generation of inducible models. Pharmacological depletion of ApoE leads 
to increase in plasma cholesterol levels at the chosen time point [38].      
Apoe-/- and Ldlr-/- mice are also used for the study of calcific aortic valve stenosis. Apoe-/- on a 
chow diet develop aortic valve stenosis phenotype with immune cell infiltration and 
calcification of aortic valve at the advanced age of 2.5 years [39], while dietary interventions 
can accelerate the phenotype [40]. In addition, hypercholesterolemic Ldlr-/- ApoB (100/100) 
mice develop valve calcification without dietary intervention at an age of 17 to 22 months [41].   
Experimental studies in mice can provide information about the in vivo pathways in 
cardiovascular diseases, although they have several differences with the humans such as size, 
lifespan, lipid profile, heart rate and also disease endpoint [29]. Combination of in vivo 
experimental animal studies with data generated in human disease set up can lead to advances 
in the understanding of the pathogenesis of cardiovascular diseases and open possibilities for 
future therapeutic approaches.  
1.5 THE IMMUNE SYSTEM 
The primary role of the immune system is to stop entrance of pathogens in the organism and 
prevent possible infection in the case of breach. However, the immune system has other crucial 
homeostatic roles that include the clearance of apoptotic cells and tissue healing. In addition, 
the immune system fights against the establishments of several kind of tumors in the body. The 
immune system is divided in two branches; the innate and the adaptive. The innate immune 
system responds rapidly to eliminate any possible threat such as pathogens. The adaptive 
response needs longer time to develop but offers the advantage of a specific response and long 
term immunological memory [42].  The main cells of innate and adaptive immune system are 
depicted in figure 1. 
Figure 1. Immune cell types. Hematopoiesis 
takes place in the bone marrow, where the 
different stem cell progenitors are generated. 
Myeloid stem cell progenitors give rise to 
polymorphonuclear cells and 
monocytes/macrophages. Lymphocytes derive 
by the lymphoid stem cell progenitors. The red 
circles indicate the innate and adaptive 
immune cells that are the focus of the current 
thesis. The schematic art pieces used in this 
figure were provided by Servier Medical art 
(https://smart.servier.com/). Servier Medical 
Art by Servier is licensed under a Creative 
Commons Attribution 3.0 Unported License.  
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1.5.1 The innate immune system  
Important roles of innate immunity are host defense against pathogens and healing after injury. 
The first innate immune barrier for infectious agents is the epithelial layer. In the case of breach 
in the epithelial layer, innate immune cells are attracted to the site for the elimination of the 
pathogen. The process of uptake of infectious agents is called phagocytosis. In order to 
recognize rapidly pathogens the innate immune system has conserved receptors for common 
pathogen structures. These receptors are called Pattern Recognition receptors (PPR) and are 
highly conserved through the species, found from the fruit fly Drosophila to humans. They 
recognize molecular sequences conserved in pathogens, the Pathogen Associated Molecular 
Patterns (PAMPs). In addition, the innate immune system can recognize endogenous danger 
signals as response to injury and cell death; the so-called Danger Associated Molecular Patterns 
(DAMPs). PPR have high specificity for the conserved sequences they recognize, however it 
differs compared to the specificity of the adaptive immune receptors. All innate immune cells 
produce the same PPR while the adaptive receptors are specific for each antigen [42].  
Neutrophils and monocytes are circulating innate immune cells that are recruited to the sites of 
infection, where they recognize and eliminate infiltrating pathogens. In case of infection, 
neutrophils are the first cells to respond and proliferate rapidly. The proliferation and 
maturation of the neutrophil progenitor cells is stimulated by colony stimulating factors (CSFs) 
[43]. Neutrophils are short-lived cells with a lifespan of few hours to few days in humans. 
Fewer numbers of monocytes are circulating in blood compared to neutrophils. Monocytes 
survive longer periods and circulate in the blood, bone marrow and spleen. Monocytes derive 
from hematopoietic stem cells from the bone marrow (Figure 1). The suggested role of 
monocytes in homeostasis include scavenging of dead cells and toxic molecules, and/or 
renewal of 'resident' tissue macrophages and dendritic cells (DCs). During inflammation due 
to tissue damage or infection, blood monocytes migrate from blood to lymphoid and 
nonlymphoid tissues in response to tissue-derived signals. They clear apoptotic cells and 
modified immunogenic molecules (such as oxidized lipoproteins), produce inflammatory 
cytokines, and can differentiate into DCs or macrophages in the infiltrated tissues [44]. 
1.5.1.1 Macrophages 
Macrophages are tissue resident cells involved in tissue surveillance, clearance of apoptotic 
cells, tissue repair and immune modulation. Tissue resident macrophages have embryonic 
origins. Renewal of tissue macrophages after birth is achieved by proliferation and infiltrating 
monocytes that subsequently differentiate to macrophages [45]. Macrophages “sample” the 
surrounding space and distinguish self from non-self/pathogenic. Nowadays, it is believed that 
macrophages are divided in several subtypes with different functions that is shown by 
differential expression of group of markers.  Most commonly macrophages are divided in two 
main subtypes; the M1 which are the one taking part in host defense by inhibitory action while 
the M2 are more involved in healing after tissue injury processes [46].  Furthermore, M2 
macrophages are divided in four subclasses; M2a, M2b, M2c, M2d [47]. M2a macrophages are 
responsible for wound‐healing. M2a macrophages express high levels of mannose receptor 
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(CD206) and contribute to tissue repair by secretion pro‐fibrotic factors such as TGF-β [47, 
48]. M2b macrophages are involved in inflammatory regulation by secretion of large amounts 
of IL-10. Similar to M2b, M2c macrophages exert anti-inflammatory functions by secretion of 
IL-10 and TGF-β and have high capacity of apoptotic cell clearance. Last, M2d macrophages, 
also called tumor associated macrophages, are characterized by high production of anti-
inflammatory cytokines and vascular endothelial growth factor (VEGF) connected to tumor 
progression and metastasis [47, 49]. Division of macrophages into M1 and M2 subtypes is a 
simplistic view, since macrophages exhibit great plasticity depending on changes on their 
microenvironment.  
Macrophages are the main phagocytic cells. One of their main roles is to facilitate the clearance 
of apoptotic cells during development and adult life. The process of removal of apoptotic cells 
from tissues is named efferocytosis. Apoptotic cells express “find me” and “eat me” signals, 
attracting macrophages in the site and facilitating the clearance [50]. They are equipped with 
several receptors that recognize these “find me” and “eat me” signals.  
Macrophages recognize and respond to different pathogens through a series of receptors such 
as the highly conserved PPRs and scavenger receptors. In order to sense PAMPs and DAMPs 
the innate immune system is equipped with 4 major classes of PPR such as the Toll-like 
receptors (TLR), C-type Lectin Receptors (CLRs), the Retinoic acid-inducible gene (RIG)-like 
receptors (RLRs) and the NOD-like receptors (NLRs). PPRs are found both on surface or 
intracellularly to cover all entries in the cell [51].   
 
Figure 2. Toll-like receptor signaling pathways and ligands. TLRs are forming hetero- and homodimers. Some 
of them are located in the cell surface membranes while the intracellular members of the family are spanning the 
endosomal membranes. Common ligands for extracellular TLRs include molecules of bacterial wall origin, while 
intracellular TLRs recognize mainly nucleic acids. Most TLRs require the adaptor molecule MyD88 and the 
downstream translocation of NF-κB for the production of pro-inflammatory cytokines. Activation of intracellular 
TLRs leads to production of pro-inflammatory cytokines through NF-κB and type I interferons through TRIF and 
IRF3 pathway. The schematic art pieces used in this figure were provided by Servier Medical art 
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(https://smart.servier.com/). Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 
Unported License. 
1.5.1.2 Toll-like receptors and signalling pathways  
TLR family is an important key in all innate response. Today 11 different TLRs have been 
recognized in humans and 13 in mouse.  TLR1, TLR2, TLR4, TLR5, TLR6 and TLR10 are 
located on the cytoplasmic membrane whilst TLR3, TLR7, TLR8, TLR9 are intracellular 
receptors and located in the endolysosomes and the endoplasmic reticulum (Figure 2). TLRs 
can also form homo- and heterodimers like TLR2/TLR6 [52]. 
 Almost all TLRs, with the exception of TLR3, require the adaptor myeloid differentiation 
protein 88 (MyD88) for downstream signaling. After TLRs encounter a specific ligand there is 
activation of two major signaling pathways. Pro-inflammatory cytokines are produced through 
nuclear factor kappa B (NF-κB) activation and type I interferons (IFN) through activation of 
interferon response factor (IRF) pathway (Figure 2) [53].  
1.5.1.3 Toll-like receptor ligands 
TLRs recognize PAMPs and DAMPs. The PAMPs include lipid based ligands of bacterial 
origin like lipoprotein polysaccharides (LPS) for TLR4, bacterial proteins like flagellin that is 
recognized by TLR5 and viral origin nucleic acids that are binding TLR3, TLR7, TLR8 and 
TLR9. TLR7 is recognizing single stranded RNA (ssRNA). Furthermore, DAMPs that are 
released during injury or cell death can also bind to TLRs [52, 54] and elicit response. 
1.5.2 The adaptive immune system 
In contrast to the innate immune system adaptive immunity offers a less rapid response but 
with increased specificity and diversity. In addition, upon encounter of a lymphocyte with an 
antigen for the first time, a primary response is formed and in parallel, there is generation of 
memory cells. The second time that a lymphocyte will encounter the same antigen, the 
secondary response as it is called, will progress more rapid, with increased magnitude and more 
effective in eliminating the antigen. The lymphocytes consist of the different T and B cell 
subsets (Figure 1) [42].      
1.5.2.1 T lymphocytes 
T lymphocytes are generated in the bone marrow and transfer to the thymus for maturation. 
They recognize mainly peptide antigens bound to Major histocompatibility complex (MHC) 
through a membrane bound T cell receptor (TCR). All T cells express the cell surface marker 
CD3, a protein that is part of the T cell receptor complex. The most usual division of T cells is 
to T helper (TH) subsets that express in addition to CD3, the CD4 and cytotoxic T lymphocytes 
(CTLs) that express CD8 in the cell surface. The role of the TH subsets is to activate the effector 
functions of macrophages and B cells, while the CTLs recognize and eliminate cells that have 
been infected or damaged and cancer cells. T cells are equipped with TCR for antigen 
recognition. TCR is a heterodimeric receptor that consists of two chains with a constant and 
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variable region. The variable region of the TCR is responsible for the recognition of the 
antigen-MHC complex [42]. 
CD4+ TH cells are divided to at least three subsets; the TH1, TH2 and TH17. Each subset 
recognizes different type of antigen and produce distinct set of cytokines. The differentiation 
into the different subsets it is determined by the microenvironment in combination with the 
invading pathogen [42].TH1 cells are mainly responsible for the stimulation of phagocytes for 
the elimination of intracellular parasites such as bacteria or viruses. The signature cytokine that 
is secreted by the TH1 cells is interferon-γ (IFN-γ). In addition, differentiation of naïve T cells 
to TH1 subset is induced by IL-12 secreted by dendritic cells [42].     
TH2 cells react against helminth parasites through activation of eosinophils. Differentiation of 
naïve T cells to TH2 is induced by the cytokine IL-4.  TH2 cells secrete IL-4 that stimulates 
antibody class switching and immunoglobulin (Ig) E antibody production, IL-5 that stimulates 
the secretion of granule content by eosinophils and IL-13 responsible for mucus secretion and 
intestinal peristalsis [42]. 
TH17 cells recruit neutrophils and monocytes to facilitate the killing of extracellular bacteria 
and fungi. TH17 cells produce IL-17 and IL-22. IL-1, IL-6, IL-23 and TGF-β lead to 
differentiation towards the TH17 subset [55]. 
Regulatory T cells (Tregs) are a T cell subpopulation with important role in immune 
homeostasis and suppression of autoimmune responses. Tregs are produced in the thymus or 
differentiate from naïve T cells in the periphery. Traditionally, they are characterized as 
CD4+CD25+FoxP3+ cells; however, other Treg subpopulations also exist. Tregs exert their 
immunosuppressive functions by several mechanisms. They suppress pro-inflammatory 
responses by production of anti-inflammatory cytokines such as IL-10 and TGF-β. In addition, 
they can downregulate inflammatory processes indirectly by depletion of extracellular ATP 
and IL-2 and thus making them unavailable for pro-inflammatory cells [56].  
1.5.2.2 B lymphocytes 
B lymphocytes are produced in the bone marrow and the final maturation stages occur in 
spleen. B lymphocytes recognize different types of antigens including proteins, 
polysaccharides, lipids, nucleic acids and small chemicals [42]. They express B cell receptors 
(BCRs) with unique antigen binding epitopes. Structurally, BCRs are membrane bound 
immunoglobulins.  The development of a specific BCR is achieved by recombination of the 
available variable (V), diversity (D), and joining (J) genes. Assembling of the recombined 
heavy and light chain polypeptides form the mature BCR [57, 58].  
Upon recognition of an antigen, naïve B cells differentiate into plasma cell and produce the 
antibodies with the specific epitopes as the one expressed on B cells as surface bound receptors. 
Antibodies are divided in five main classes, which are IgA, IgD, IgE, IgG and IgM.  In addition, 
the immunoglobulin classes differ structurally and in capacity of secretion and undergo 
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posttranslational modifications [59]. Naïve B cells bear in their membranes antibody bound 
receptors IgM and IgG. 
B lymphocytes are divided into B1 and B2 cells. The B1 cells are responsible for the 
surveillance of the peritoneal and mucosal cavities. B1 cells recognize mainly non-protein 
antigens and produce naturally occurring antibodies in a T cell independent manner. B2 cells 
are located in the spleen and are divided in follicular and marginal zone (MZ) B cells. 
Developmental and environmental factors lead to differentiation of B2 into the different subsets 
[60]. MZ and follicular B cells remain in the spleen in mice [61], while in humans MZ-like 
cells have been also found in circulation [62]. Follicular B cells interact with T follicular helper 
cells (TFH), become germinal center (GC) cells and produce high affinity antibodies against 
protein antigens [63]. MZ B cells are located in the periphery and recognize blood born 
antigens. Upon encounter with an antigen MZ B cells produce fast T cell independent 
antibodies.  MZ and B1 derived plasma cells are short lived and produce fast, low affinity 
antibodies. MZ and B1 cells are able to produce mainly IgM antibodies. On the other hand, 
plasma cells derived by follicular B cells and GC formation, are long lived and keep antibody 
titers steady for several years. Follicular B cells have the capacity to produce all 
immunoglobulin isotype classes through class-switching [59, 64].    
1.5.3 Tissues of the immune system  
The tissues of the immune system consist of the thymus and bone marrow, the generative 
lymphoid organs, and the lymph nodes, the spleen, the mucosal and cutaneous immune 
systems, known as peripheral lymphoid organs. The role of the peripheral lymphoid organs is 
to promote the development of immune responses. In the peripheral lymphoid organs, T cells 
and B cells reside closely with the antigen presenting cells (APCs). APCs concentrate antigens 
in the peripheral lymphoid organs and enable responses from T and B cells [42].  
The peripheral lymphoid organs filter the lymph, the blood, the skin, the gastrointestinal and 
respiratory tracts for antigens. The lymph nodes are located along the lymphatic channels and 
their role is to filter and capture antigens that circulate in the lymphatic vessels. The substances 
that arrive in the lymphatic system derive from the epithelia and several tissues. The spleen is 
a highly vascularized organ that filters the blood for blood born antigens. Dendritic cells and 
macrophages capture blood born antigens. The abundant phagocytes in the spleen eliminate 
many of the antigens circulating in the blood.   The cutaneous and mucosal immune systems, 
such as the tonsils and intestinal Peyer´s patches recognize pathogens that breach the 
epithelium [42].  
Most of the peripheral lymphoid organs have defined morphology divided into different 
anatomical compartments. The spleen consists of the red and white pulp. These two regions 
are separated by the marginal zone (MZ). The red pulp is responsible for removing from the 
circulation dead, opsonized cells and aged red blood cells. Furthermore, red pulp has the role 
to filter the blood for pathogens and molecules connected to tissue damage. Several innate 
immune cells such as macrophages and dendritic cells are located in the red pulp, although the 
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white pulp is primarily responsible for the generation of immune responses. Upon recognition 
of a pathogen in the red pulp, several cells such as T cells and plasma cells will migrate in the 
red pulp for the elimination of the pathogen. The white pulp consists of distinct zones where 
the B and T cells are located. In the white pulp B cells reside in the follicles while T cells are 
located in the periarteriolar lymphoid sheath. The marginal zone that acts as a bridge between 
the white and red pulp is populated by MZ B cells and two macrophage subsets; the marginal 
zone macrophages and the marginal metallophilic macrophages. Lymph nodes have similar 
morphology with the spleen. However, in contrast to the spleen, lymph nodes have a capsule 
that separates the different compartments and also pathogens are entering the lymph nodes 
through the lymphatic vessels that are absent in the spleen [65].  
1.6 BRIDGING INNATE AND ADAPTIVE IMMUNITY 
For a long time it was believed that innate and adaptive immune system act individually. Since 
the innate immune system is highly evolutionarily conserved, it was perceived as more 
primitive and the interest in immunological research was shifted towards the adaptive immune 
system. However, long time after the innate and adaptive immune system was described the 
effects of innate immune system on adaptive response were highlighted [66].   
Key players in the bridging of innate and adaptive immunity are the dendritic cells and pattern 
recognition receptors. Successful adaptive immune activation requires three signals. The first 
signal is the antigen presentation from DCs to T cells [67]. The second signal is the upregulation 
of costimulatory molecules due to activation of PPRs in the DCs by PAMPs. The third is the 
production of innate cytokines by DCs that facilitate T cell differentiation [68, 69].   
TLR activation plays a central role in innate modulation of the adaptive immunity. Activation 
of TLRs enhanced antigen presentation by increasing phagocytic processes.  Studies have 
shown that TLR4 activation increased antigen cross presentation to  CD4 T cells [70], while 
activation of the intracellular TLRs by nucleic acids enchanted antigen presentation and led to 
activation of CD8 T cells [68, 71].   
More evidence is accumulating regarding the expression of TLR in cells of the adaptive 
immune system. Studies have shown that both T and B cells express TLRs [72, 73]. In addition, 
TLR ligands have been shown to activate T cells and B cells in vitro.  Stimulation of human 
purified T cells in vitro stimulated proliferation and cytokine secretion from CD4+ T cells [72].   
MZ B cells express high levels of TLRs [74]. It has been shown, that LPS leads to dual 
stimulation of BCR and TLR that results in fast production of high affinity antibodies [75].    
In conclusion, cells such as DCs and MZ B cells facilitate the bridging of innate and adaptive 
immunity. In addition, expression of pattern recognition in DCs and adaptive immune cells is 
required for a successful adaptive immune response.  
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1.7 PATHOGENESIS OF ATHEROSCLEROSIS AND AORTIC VALVE 
STENOSIS 
1.7.1 Atherosclerosis 
The initiation of atherosclerotic lesions is already happening early in life with the development 
of fatty-streaks during adolescence, which progressively leads to the formation of advanced 
lesions with the accumulation of lipids, immune cell infiltration and structural reorganization. 
Atherosclerotic lesions are formed in the intima layer of the artery [5, 76]. Arteries structurally 
consist of three layers; the intima, media and adventitia. High LDL cholesterol levels in the 
circulation lead to infiltration and accumulation of LDL in the intimal layer. The infiltrated 
LDL particles are no longer protected by antioxidant factors that are present in the plasma and 
undergo several modifications including oxidation. The modified LDL particles gain pro-
inflammatory properties that lead to attraction of monocytes in the site. Monocytes enter the 
lesions by binding to adhesion molecules like vascular cell adhesion molecule (VCAM) and 
intercellular adhesion molecule (ICAM) expressed by the activated endothelium. In the intima, 
the infiltrated monocytes differentiate into macrophages and express scavenger receptors that 
will facilitate the uptake of LDL particles. Uptake of large amount of LDL particles by 
macrophages eventually leads to foam cells formation (Figure 3). Increased apoptosis of foam 
cells in the plaques leads to inflammatory responses and the formation of a big necrotic plaque. 
In the hyperlipidimic environment within the plaque, other macrophage functions such as 
cholesterol efflux and efferocytosis are also dysregulated [77]. Subsequently, there is 
infiltration of T cells in the intima that play immunomodulatory role, regulating the functions 
of the neighboring cells, such as macrophages, endothelial and smooth muscle cells. Secreted 
mediators of the accumulating leukocytes lead to smooth muscle cell (SMC) migration from 
the media layer to the intima, in the site of the progressing lesion [78].     
 
Figure 3. Pathogenesis of atherosclerosis. Infiltration and modification of LDL in the intima, leads to recruitment 
of monocytes that enter the site through adhesion molecules expressed by the activated endothelium. Macrophages 
in the lesions uptake LDL and become lipid loaded foam cells. Attraction of T cells in the lesion promote a pro-
inflammatory phenotype. In addition, advanced lesions are characterized by smooth muscle cell differentiation, 
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migration, and changes of the extracellular matrix. For long time the focus was primarily influx of leukocytes from 
circulation but nowadays more evidence exist that secondary and tertiary lymphoid organs formed in the adventitia 
are involved in the progression of atherosclerosis. The schematic art pieces used in this figure were provided by 
Servier Medical art (https://smart.servier.com/). Servier Medical Art by Servier is licensed under a Creative 
Commons Attribution 3.0 Unported License.     
Endothelial cells are mostly quiescent however; they can be activated in response to 
pathological stimuli such as disturbed blood flow. Low laminal shear stress in vessel areas such 
as bifurcations, prone to develop atherosclerotic lesions, results in activation of pro-
inflammatory pathways in endothelial cells [79]. In the intima cytokines, chemokines and 
growth factors secreted by the activated endothelium induces the proliferation and extracellular 
matrix synthesis by smooth muscle cells, hence initiating generation and remodeling of the 
developing atherosclerotic lesions [80]. A study has shown that endothelial endoplasmic 
reticulum stress and apoptosis results in endothelial erosion and subsequently in thrombus 
formation [81].  
Smooth muscle cells are the main cell type constructing the vessel wall. During atherogenesis 
vascular remodeling takes place. Proliferation of smooth muscle cells has been connected to 
protective effects by increasing plaque stability [82]. In contrast, SMC migration and apoptosis 
due to inflammation and enzymatic activity contribute to plaque rupture [83]. Investigation of 
the Biobank of Karolinska Endarterectomies (BiKE) (see below, 3.1, Methodological 
Considerations) led to identification of a convertase involved in processes of plaque instability. 
The proprotein convertase, PCSK6 was shown to be increased in symptomatic compared to 
asymptomatic patients and was expressed mainly in SMC located in the fibrous cup [84]. A 
recent study of the same group showed that PCSK6 is a key regulator of SMC processes such 
as proliferation and migration [85]. Furthermore, the role of SMC cells in atherosclerosis 
depends on the origin of the cells. One general view suggests that SMC are atheroprotective 
whilst macrophages promote the disease [86] but the picture is more complex. Plaques with 
high macrophage numbers and fewer SMC are vulnerable and prone to rupture.  However, 
several human and mice studies have shown that SMC within the plaque positive for traditional 
SMC markers express also macrophage markers like CD68, indicating transition into 
macrophage–like cells [87-89]. These cells have lower capacity of lipid and apoptotic cell 
clearing compared to macrophages thereby leading to increased inflammation. Stress induced 
apoptosis of SMC can lead to fibrous cap thinning and rupture, commonly in the shoulder 
region of the plaques. SMC cells can be beneficial by the protection of fibrous cap and plaque 
repairing but macrophage –like SMCs have a pro-atherogenic role [86]. 
Extracellular matrix (ECM) remodeling and degradation is involved in the pathogenesis of 
several cardiovascular diseases. ECM facilitates the adaptation of the vascular wall to 
mechanical forces. ECM includes 3 components, the proteoglycans that are located in the 
subendothelial space and the elastic fibers and collagens that are located in the tunica media 
together with vascular smooth muscle cells [90].  Single nucleotide polymorphism at the 
COL4A2 locus was associated with decreased atherosclerotic plaque stability and increased 
coronary heart disease risk [91]. Versican, the main proteoglycan in the vessel wall, is 
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associated with pro-atherogenic processes. Versican has been connected with LDL retention in 
the subendothelial space [92]. The retained LDL is subsequently removed by macrophages that 
progress to foam cells and thus enhancing plaque development. In another study, depletion of 
the perlecan heparin sulfate proteoglycan increased experimental atherosclerosis. The mice 
presented increased smooth muscle cell content. These results indicate a detrimental role for 
perlecan in atherosclerosis [93].    
Especially sensitive sites for atherosclerosis development are coronary and carotid arteries. The 
atherosclerotic lesion grows slowly and silently, starting with fatty streak formation before the 
age of 30 and finally reaching an advanced fibrotic plaque 30-40 years later. The lesions are 
complex in their structures, and show a high degree of infiltrating immune cells such as 
macrophages and T cells. The actual event leading to an infarction, is the rupture of a plaque 
followed by thrombus formation that either occlude the vessel on site or embolises. Plaques 
that are prone to rupture are called vulnerable or unstable plaques [94]. Inflammatory 
components are often greatly involved in the dangerous atherosclerotic plaque rupture [94]. 
Several studies from the last years have put the spotlight on specific subtypes of macrophages 
as being a driving force in plaque rupture [95]. 
1.7.2 Aortic valve stenosis 
Calcific aortic valve stenosis (CAVS) develops due to the gradual remodeling of the aortic 
valve. The normal aortic valve consists of three leaflets and called tricuspid aortic valve. 
However, 0.5-1% of individuals have a congenital abnormal bicuspid aortic valve due to 
incomplete separation during embryogenesis [96, 97]. Individuals with bicuspid valves develop 
some type of aortic pathology, in which mineralization of the aortic valve occurs in response 
to several factors such as genetic, hemodynamic and mechanical forces [98]. The most 
common aortic pathology in individuals with bicuspid valve is CAVS that develops 
approximately two decades earlier compared to individuals with tricuspid valves [99]. 
Differences between tricuspid and bicuspid valve patients in the pathogenesis of the disease 
have been also shown by differential expression of gene profiles with upregulation of 
inflammatory genes only in tricuspid valve patients [100]. The most important risk factors for 
developing CAVS is age and bicuspid valve. Other factors include smoking, hypertension, 
hypercholesterolemia, obesity and renal failure [99, 101-103]. In addition, genetic risk factors 
have been implicated in the pathogenesis of CAVS [104].  
Lipoprotein deposition, immune cell infiltration and differentiation of cells towards an 
osteoblastic phenotype lead to active leaflet calcification. The human aortic valve is 
constructed by three leaflets. Each leaflet is composed by the fibriosa facing the aorta, the 
spongiosa and the ventricularis located in the left ventricular tract. The main cell type 
composing the aortic valve are the valve interstitial cells (VICs). Aortic valves also contain few 
smooth muscle cells and endothelial cells that cover the ventricular and aortic surfaces [99].  
Endothelial damage due to mechanical stress and pro-inflammatory mediators allows the 
infiltration of LDL to the subendothelial space. LDL retention in the valve leaflets attracts 
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immune cells at the site. Macrophages, T and B cells are the main immune cells that infiltrate 
aortic valves [105, 106]. Reactive oxygen species and enzymes produce lysophospholipid 
derivatives that activate pro-inflammatory pathways and osteogenic differentiation of VICs. 
Imbalance of matrix metalloproteinases and their inhibitors in the valve lead to disorganization 
of fibrous tissue. Macrophages and VICs actively promote calcification by deposition of 
macrovesicles. Furthermore, production of leukotrienes and prostaglandins promote expression 
of osteogenic genes and valve mineralization of VICs in vitro [107]. Taken together, lipid 
modification leads to immune cell and activation of pro-inflammatory and osteogenic pathways 
that actively contribute to the progression of calcific aortic valve stenosis. 
1.7.3 Innate immunity in cardiovascular disease 
 Several studies have shown that innate immune cells and receptors play important role in the 
pathogenesis but also in the regression of atherosclerosis. Macrophages and TLR activation are 
highly involved in these processes. In addition, macrophage activation and innate immune 
signaling is implicated in the pathogenesis of CAVS.     
Macrophages 
High numbers of macrophages used to indicate plaque instability. However, nowadays the 
macrophage phenotype is more important than the number. Both M1 and M2 macrophages are 
present in human lesions [108]. Pro-inflammatory M1 macrophages are located in higher 
numbers in the shoulder regions than are prone to rupture while M2 anti-inflammatory 
macrophages are mostly found in the fibrous cap or the adventitia [109, 110]. This suggest that 
M2 macrophages could balance the detrimental effects of M1 through their healing/reparative 
capacities. M1 and M2 macrophages that have been identified in the plaque differ in their lipid 
content. M1 macrophages contain more intracellular lipids than M2 [111]. As previously 
discussed the M1 versus M2 classification is an oversimplification. Macrophage phenotype 
depends on tissue microenvironment. Mox is a macrophage phenotype that has been identified 
in atherosclerotic lesions and is activated by the presence of oxidized phospholipids [112].  
Furthermore, a recent study has shown that recruitment of Ly6Chi monocytes to the lesions and 
differentiation towards M2 macrophage phenotype resulted in atherosclerosis regression [113]. 
Several macrophage functions such as efferocytosis, are defective in atherogenic environment 
[114].  Ca2+/calmodulin-dependent protein kinase II (CaMKII), that is responsible for the 
regulation of Ca2+ related processes, inhibited efferocytosis pathways in macrophages. 
Depletion of CaMKII in atherosclerotic mice improved plaque stability with smaller necrotic 
cores [115]. In addition, arginine metabolism through arginase 1 in macrophages enhanced 
clearance of apoptotic cells. Lack of arginase 1 in atherosclerotic mice was accompanied with 
defective efferocytosis in vivo [116]. 
Similar effect in disease outcome for the different macrophage subsets was observed in calcific 
aortic valve stenosis. M1 macrophages were associated with enhanced calcification of VICs in 
an in vitro co-culture model of human VICs and M1 macrophages stimulated with LPS [117]. 
M1 macrophages were significantly increased in calcified compared to non-calcified human 
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aortic valves. In the same study, transfer of conditioned media from M1 macrophages to human 
VICs in vitro increased osteogenic gene expression [118].      
1.7.4 TLR effect in cardiovascular disease 
The role of most TLRs has been investigated in atherosclerosis. The cell surface TLRs have 
been mainly associated with detrimental effect when it comes to atherosclerosis. In contrast, 
the intracellular receptors are connected to protective effects.  
TLR ligands in cardiovascular disease 
 Both exogenous and endogenous TLR ligands have been associated with development and 
exacerbation of atherosclerosis.  Most of the exogenous TLR ligands are of bacterial origin, 
like Tri-acyl lipopeptides, peptidoglycans and liposaccharide [119].  Tlr2-/-xLdlr-/-mice 
presented decreased atherosclerosis indicating an endogenous ligand. In the same study, 
administration of the synthetic TLR2 ligand Pam3CSK4 exacerbated atherosclerosis in Ldlr-/- 
mice [120].  Peptidoglycans, a gram-positive bacterial component, was detected in human 
atherosclerotic plaques and correlated with instability [121]. In addition, atherosclerosis was 
accelerated after LPS administration to hypercholesteraemic mice [122].  
Established endogenous ligands in atherosclerosis are derived from lipoprotein modifications, 
vascular injury and cell death. Minimally modified low density lipoproteins (mmLDL), 
oxidized LDL (oxLDL) and ApoCIII (very-low-density LDL component) serve as ligands for 
CD14/MD-2/TLR4 complex, TLR4/TLR6 heterodimer and TLR2 respectively. Another 
endogenous atherosclerotic ligand is the high mobility group box 1 (HMGB1) that signals 
directly through TLR2 and TLR4 ligands. One described indirect effect of HMGB1 is 
activation of the intracellular TLR9 through DNA-immune complexes [123].    
TLR2 / TLR4  
Several TLRs have detrimental role in atherosclerosis. TLR2 and TLR4 ApoE knockout mice 
presented decreased atherosclerosis [124]. In addition, activation of TLR2 in the human plaque 
endothelium lead to up-regulation of adhesion molecules and attraction of neutrophils that 
elevated inflammation and loosened the endothelial layer causing superficial erosion. This type 
of erosions release debris in the vessel lumen accompanied with a dangerous thrombus 
formation [81]. Studies have shown that TLR2 and TLR4 are expressed in VICs and their 
activation contributes to the pathogenesis of CAVS. In vitro activation of TLR2 and TLR4 in 
human derived aortic VICs resulted in increased expression of pro-inflammatory cytokines and 
osteogenic genes [125, 126]. 
TLR3 
Surprisingly, Apoe-/-xTlr3-/- indicated a protective role of the receptor against atherosclerosis, 
shown by increased atherosclerotic burden in Apoe-/-xTlr3-/- and by mechanical arterial injury 
[54]. However, there are other murine studies showing that TLR3 facilitates extracellular 
matrix degradation through the control of matrix metalloproteinase 2 (MMP-2) [127]. Its role 
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in hematopoietic knockout of the downstream regulators TRIM and tumor necrosis factor 
receptor (TNF-R)-associated factor (TRAF) decreased atherosclerosis [128]. Furthermore, the 
synthetic ligand Poly (I:C) promoted calcification in human AVICs. The effect was mediated 
by stimulation of pro-inflammatory and osteogenic factors such as the bone morphogenetic 
protein-2 (BMP-2) and alkaline phosphatase (ALP) [129].   
TLR7  
Several studies have been performed for the elucidation of the role of TLR7 in atherosclerosis.  
In a murine study in collaboration with our group Apoe-/-xTlr7-/- mice presented increased 
atherosclerosis, with big necrotic core and M1 macrophage infiltration in the lesions. In the 
same study, TLR7 transcript in human carotid plaques, part of the Biobank of Karolinska 
Endarterectomies was correlated with M2 anti-inflammatory markers, indicating that TLR7 is 
important for the switch of macrophages towards a more healing, anti-inflammatory phenotype 
[130].  In another study, depletion of Interferon factor 5 (IRF5) a downstream mediator upon 
TLR7 and TLR9 activation lead to aggravated atherosclerosis in lupus mouse model. The effect 
was mediated by decrease in anti-inflammatory cytokine IL-10. IRF5 is a necessary mediator 
for the production of IL-10 downstream of TLR7 [131]. Furthermore, stimulation with a TLR7 
ligand led to increase in patrolling monocytes in circulation, similar to atherosclerotic 
conditions. Patrolling monocytes have been shown to have protective role against endothelial 
damage. These data indicate a protective role for TLR7 activation in atherosclerosis through 
effects in circulating immune cells [132].  
In contrast to the previous data, two recent studies have shown detrimental effects for TLR7 in 
atherosclerosis. Apoe-/-xTlr7-/- were protected against diet induced atherosclerosis [133]. In the 
same line stimulation of atherosclerotic mice with a TLR7 ligand promoted lesion formation 
[134]. The role of several TLRs in atherosclerosis is not clarified yet. Contradictive data have 
been presented in some studies. This discrepancy may be explained through differences in 
species, ligand and stage of the disease and prompts further investigations.  
Currently there is not so much evidence regarding the role of TLR7 in calcific aortic valve 
stenosis. The study of TLRs in CAVS has been mainly studied in isolated human VICs in vitro. 
TLR7 is expressed in VICs in very low levels compared to the highly expressed TLR2 and 4. 
In addition, stimulation of human VICs with the synthetic TLR7 ligand imiquimod in vitro did 
not yield NF-κB activation indicating inactivity of TLR7 in human VICs [135]. However, 
stenotic aortic valves are infiltrated by several immune cells that have been shown to express 
the receptor. More studies are required for the investigation of the role of TLR7 in CAVS.  
1.7.5 Adaptive immune cells in cardiovascular disease 
T lymphocytes 
Several studies have been conducted in order to clarify the role of each T cell subset in the 
athersoclerostic lesions. T cells have been localized mainly in the fibrous cup of atherosclerotic 
lesions. CD4+ T cells constitute the predominant subtype in atherosclerotic plaques [13]. In 
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addition, T cells have been shown to recognize ApoB100 through antigen presentation from 
APCs. Blocking of this response by immunization in atherosclerotic mice decreased disease 
burden [136].  
CD4+ TH cell subsets (TH1, TH2, TH17 and Treg) are extensively studied with controversial 
results for some of the subsets. TH1 are the main producers of INF-γ, an abundant pro-
atherogenic cytokine present in lesions [137]. Secretion of IFN-γ in the plaque inhibited antigen 
presentation processes, differentiation and proliferation of smooth muscle cells [138, 139]. In 
addition, INF-γ can inhibit the maturation of collagen fibers and thus affect the stability of the 
fibrous cap [140]. The role of TH2 cells is not clarified yet. The atherosclerotic environment, 
specifically severe increase in cholesterol levels resulted in a shift of TH1 cells towards TH2 
[141]. Furthermore, depletion of TH2 related cytokines such as IL-4 and IL-13 resulted in 
contradictory effects with both promoting and inhibiting the progression of atherosclerosis 
respectively [142, 143]. Decreased intima/media thickness was associated with increased 
numbers of TH2 cells in blood and lower risk for women of having an MI [144]. TH17 cells is 
another TH subset with conflicting effects in atherosclerosis. Depletion of IL-17A, the signature 
cytokine of TH17 cells resulted in contradictory results in atherosclerosis with both acceleration 
[145] and reduction [146] in lesion size. IL-17A promoted plaque stability through stimulation 
of collagen production by smooth muscle cells [147].  
Regulatory T cells  
Multiple studies indicate that Tregs have anti-inflammatory properties and decrease 
atherosclerosis. Depletion of Tregs with anti-CD25 antibodies increased disease burden in  
atherosclerotic mice [148]. In addition, depletion of Tregs resulted in aggravation of 
atherosclerosis and increase in plasma cholesterol levels. These data indicated that Tregs 
protect against atherosclerosis by modifications on lipoprotein metabolism [149]. Dendritic cell 
vaccination recognizing FoxP3, resulted in reduction of Foxp3+ T cells in several organs and  
had detrimental effect in atherosclerosis with increased immune cell infiltration in the lesions 
[150]. Transfer of Tregs is protective [151]. In addition, expansion of Tregs by pharmacological 
intervention such as anti-CD3 or Vitamin D3 administration, decreases atherosclerosis [152, 
153]. Another study has shown that Treg expansion led to regress of atherosclerotic lesions 
[154].  Furthermore, Tregs play different role in the stages of atherosclerosis with decreased 
atherosclerosis in the initiation and plaque stabilization in advanced lesions [155].  
B lymphocytes 
The first indication that B cells play important role in atherosclerosis was shown by the 
presence of immunoglobulins in the atherosclerotic plaques [156-158]. Caliguiri et al have 
shown a functional role for B cells in atherosclerosis. In this study, Apoe-/- mice that were 
splenectomized presented increased atherosclerosis. When the investigators adoptively 
transferred B cells back to splenectomized mice the effect on atherosclerosis was abrogated 
[159]. Furthermore, hypercholesterolemic mice injected with apoptotic cells induced protective 
B cell response within the spleen. The treatment led to expansion of B1a and MZ cells [160]. 
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Transfer of bone marrow cells from B cell deficient mice to irradiated Ldlr-/- mice led to 
increased atherosclerotic burden [161]. Another recent study has shown that high cholesterol 
diet activated an anti-inflammatory program in the spleen where marginal zone (MZ) B cells 
controlled T follicular helper cells [162].  In addition, memory B cells have been correlated to 
better outcome with fewer reoccurring cardiovascular events in a human cohort of patients 
undergoing carotid endarterectomy [163]. 
  Humoral immunity 
The role of immunoglobulins in atherosclerosis have been studied both in human disease and 
through experimental animal models. As previously described, during atherogenesis LDL 
undergoes several modifications such as oxidation, acetylation and methylation. It has been 
shown that antibodies against oxidation specific epitopes (OSEs) are infiltrated in 
atherosclerotic lesions [164]. Except for LDL molecule, OSEs have been discovered in 
apoptotic cells, damaged proteins, microvessels and bacteria [165].  Specifically, antibodies 
recognize the phosphatidylcholine group (PC) in both oxLDL and apoptotic cells.  
Contradictory effects have been described by several studies regarding the role of IgG 
antibodies in cardiovascular disease. In a human cohort anti-OxLDL IgG levels were associated 
with increased cardiovascular events in participants. The effect was more profound for 
individuals of black ethnicity [166].  Furthermore, meta-analysis of seven studies have shown 
association of anti-oxLDL IgG with increased risk for atherosclerosis related cardiovascular 
events [167].  However, in vivo experimental studies have indicated a protective role for IgG 
antibodies in atherosclerosis. Intravenous administration of polyreactive IgG to Apoe-/- mice 
inhibited early and advanced atherosclerosis [168]. In addition, injection of IgG antibodies 
against malondialdehyde-modified apoB-100 resulted in regression of atherosclerotic lesions 
[169]. Adoptive transfer of LDL-reactive T cells promoted the production of T cell dependent 
anti-LDL antibodies that mediated plasma cholesterol decrease in the human APOB100-
transgenic Ldlr-/- mice [170].  Furthermore, IgG antibodies promoted smooth muscle cell 
proliferation and thus atherosclerotic plaque stability [171]. More studies are necessary in order 
to elucidate the role of IgG antibodies in cardiovascular disease.   
 In contrast, IgM is associated with protective pathways in cardiovascular disease. Several 
experimental model studies and human cohorts have demonstrated a protective role of IgM 
antibodies in atherosclerosis. Human cohorts have negatively associated high levels of IgM 
antibodies against OxLDL and MDA-LDL with the risk for cardiovascular events [166, 172].  
Lack of the soluble IgM due to genetic depletion resulted in increased disease burden and IgM 
reconstitution conveyed protection against atherosclerosis [173, 174]. Initially, the protective 
role of anti-oxLDL IgM antibodies was demonstrated by cloning the E06 IgM recognizing 
oxidized phospholipids from the spleens of atherosclerotic mice. In vitro assays have 
demonstrated the capability of E06 IgM to inhibit OxLDL uptake by macrophages [175, 176]. 
In addition, passive immunization of Apoe-/- mice with T15/E06 IgM antibodies against PC 
epitope ameliorated vein graft atherosclerotic lesion size [177]. However, depletion of the V1 
(VHS107.1.42) immunoglobulin heavy chain gene that is required for the production of T15 
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IgM antibodies in atherosclerotic mice  did not affect the disease burden [178]. Another 
protective pathway in atherosclerosis that IgM against OSEs are involved is the clearance of 
apoptotic cells through epitope mimicry. As it was discussed above, apoptotic cells share 
common epitopes with oxidized phospholipids such as PC. The involvement of IgM antibodies 
in apoptotic cell clearance has been shown in several studies. Transfer of apoptotic cells in 
hypercholesterolaemic mice resulted in increase of OSEs IgM antibodies and decreased 
atherosclerosis. The effect was abrogated in B cell deficient mice [160]. Furthermore, in an 
experimental set up where apoptotic cells were mimicked by transfer of PC liposomes in 
atherosclerotic mice, B1a cell numbers and total IgM levels were increased with an 
accompanied decrease in disease burden [179].  
1.8 MEDIATORS IN CARDIOVASCULAR DISEASE 
Both pro- and anti-inflammatory mediators play important role in all stages of atherosclerosis.  
Several groups of mediators are involved in the atherosclerotic processes; cytokines of different 
classes including interleukins, tumor necrosis factors, interferons, colony-stimulating factors 
and transforming growth factors. 
Cytokines     
TNF-α and IFN-γ are two pro-atherogenic cytokines with multiple effects on several cell types 
within the plaque. They have been shown to alter endothelial cell function like distribution, 
junction disruption and up-regulate the expression of chemokines and adhesion molecules. 
These result in increased transmigration of immune cells in the lesion [180]. In addition, IFN-
γ facilitates the formation of foam cells by increasing the expression of scavenger receptors 
and inhibits the cholesterol efflux by decreasing the expression of ATP-binding membrane 
cassette transporter 1. Furthermore, both IFN-γ and TNF-α are responsible for macrophage and 
smooth muscle cell death. TNF-α is inducing broad production of MMPs and decreases the 
antithrombotic functions of endothelial cells. It was shown that Apoe-/- mice TNF-α deficient 
had reduction in their lesion size [180].  IL-12 is another cytokine with pro-atherogenic role. 
IL-12 induced TH1 cell proliferation due to the increase of the transcription factor Tbet [181].  
IL-10 is the most potent anti-inflammatory cytokine in the plaque, produced by M2 
macrophages, Treg, TH2 and some TH1 cells in the lesions. The double knock out model Apoe
-
/- deficient for IL-10 had pronounced phenotype with increased lesion formation, inflammatory 
cell infiltration and pro-inflammatory cytokine production. On the contrary, increased IL-10 
serum levels in patients of acute coronary syndromes were correlated with better prognosis 
[182]. IL-10 modulates several macrophage functions that promote atherosclerosis [183].These 
functions include inhibition of the secretion of pro-inflammatory cytokines, the expression of 
adhesion molecules and MMPs. That results in less infiltration of monocytes in the lesions and 
increases stability. Furthermore, a recent study showed that IL-10 polarizes macrophages 
towards the anti-inflammatory type M2. IL-10 has anti-apoptotic effects by increasing the 
expression of genes like Bfl-1 and Mcl-1. Another protective modulation of IL-10 is the 
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increase in cholesterol uptake from macrophages in combination to increased cholesterol influx 
that prevents foam cell formation [183]. 
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a growth factor that 
promotes the maturation of dendritic cells and monocytes from bone marrow. The role of GM-
CSF in atherosclerosis has not been well clarified yet. Atherosclerosis was increased in the 
Apoe-/-xGm-csf-/- mice indicating protective effect [184]. However, the opposite effect was 
observed in Ldlr-/-xGm-csf-/- mice [185].  
Type I IFN  
Type I interferons are mainly produced by dendritic cells and macrophages after the activation 
of intracellular TLRs. Their role in atherosclerosis seems to be detrimental. IFN-α increases 
the expression of scavenger receptors and upregulates the uptake of ox-LDL leading to 
formation of foam cells [186]. Treatment of Apoe-/- and Ldlr-/- mice with IFN-β increased the 
secretion of chemokine CCR5 that lead to increased monocyte infiltration in the lesions [187].   
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2 AIMS 
The present thesis aimed to investigate the role of the Pattern Recognition Receptor TLR7 in 
atherosclerosis and calcific aortic valve stenosis. 
The specific aims were to: 
I. Investigate the role of TLR7 in advance human carotid plaques 
II. Explore the effect of TLR7 in calcific aortic valve stenosis in the different 
macrophage subsets 
III. Identify activated pathways upon in vivo stimulation with a TLR7 ligand in 
experimental atherosclerosis 
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3 METHODOLOGICAL CONSIDERATIONS 
3.1 BIOBANK OF HUMAN CAROTID ATHEROSCLEROTIC PLAQUES 
The Biobank of Karolinska Carotid Endarterectomies was established in 2001 in collaboration 
between the Experimental Cardiovascular Research Unit at Karolinska Institutet and the 
Department of Vascular Surgery at Karolinska University Hospital. The biobank consists of 
samples and data from approximately 1000 patients. Carotid plaques removed under carotid 
endarterectomy (CEA) are collected, also including from each patient plasma, RNA from 
PBMC, and DNA. All operated patients presented more than 70% occlusion according to the 
North American Symptomatic Carotid Endarterectomy Trial, NASCET criteria [188]. Several 
of the patients experienced symptoms such as minor stroke, amaurosis fugax and transient 
ischemic attacks.  In addition, BiKE includes transcript profile data of carotid plaques and 
clinical data. Non-atherosclerotic normal arteries were obtained from 10 macroscopically 
disease-free iliac arteries or aorta from organ donors without a history of cardiovascular disease 
at Karolinska University Hospital. 
Specific aim for our group in the BiKE cohort has been to study inflammation and immune 
response in patients with severe atherosclerosis by using transcript profiling. In addition, we 
aimed to investigate whether clinical parameters and patients´ outcome can be correlated to 
transcriptional profiles. The above types of analyses has led to identification of several key 
molecules in atherosclerosis [85, 189-192]. The publicly available BiKE dataset has been also 
utilized by external users, such as in a recent publication of immune cell atlas for atherosclerotic 
plaque [193]. 
3.2 FOLLOW UP AND DEFINITION OF EVENTS 
In order to investigate the effect of TLR7 in patients´ outcome in Paper I, BiKE database was 
merged with the Swedish Hospital Discharge Register and the Swedish Cause of Death 
Register. Follow-up data of adverse cardiovascular, cerebrovascular, and vascular events for 
all patients included in the cohort were collected from the above registers. MACCE were 
defined as the combined incidence of myocardial infarction, stroke, percutaneous coronary 
intervention, coronary artery bypass grafting, endovascular intervention of peripheral arteries, 
and open surgery on peripheral arteries, as reported to the registers listed above. Ischemic 
events were defined as fatal or nonfatal myocardial infarction or ischaemic stroke.  All causes 
of death other than MACCE were excluded. The retrieval of myocardial infarction and stroke 
incidence data from the Swedish Hospital Discharge Register and the Swedish Cause of Death 
Register is a reliable, validated alternative to the use of revised hospital discharge and death 
certificates. The total number of MACCE and MI events in the microarray discovery cohort 
was 34 and 24, respectively. In the qPCR validation cohort, 47 MACCE and 33 MI events 
occurred. 
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3.3 BIOBANK OF HUMAN AORTIC VALVES 
Tricuspid aortic valves were collected from patients undergoing aortic valve replacement 
surgery at Karolinska University Hospital, Solna. All patients have given written consent 
according to the Declaration of Helsinki and the local ethics committee. The valves used for 
microarray analysis were collected in RNAlater. Each valve was macroscopically divided in 
healthy, intermediate and calcified part. For ex vivo and in vitro assays and histological analysis 
the valves were collected in Dulbecco's Modified Eagle Medium (DMEM).   
3.4 EX VIVO CULTURE OF HUMAN CAROTID ATHEROSCLEROTIC 
PLAQUES AND AORTIC VALVES 
Fresh carotid plaques were obtained from patients undergoing CEA at Karolinska University 
Hospital, Solna. At the operation day, the plaque tissue was cut into small pieces (2 mm3), 
distributed into the wells of a 48-well plate and thereafter pre-incubated for 1 h in RPMI 1640 
medium supplemented with 10% human serum at 37 oC in 5% CO2 before stimulation with 
TLR7 agonist imiquimod (IMQ) (Figure 4). In the case of carotid plaques 2.5, 5, or 12.5 µg/mL 
IMQ was used in a dose–response challenge. Each dose was run in duplicates and the reported 
values are the average for each concentration. As a control, 100 ng/mL LPS was added to assure 
that live cells were present in the tissue after the mincing and that innate response was intact. 
After 20 h of stimulation, supernatants from the plaques were collected and stored for cytokine 
analysis.  
In Paper II the ex vivo set up with tissue from aortic valve replacement was performed in the 
same way as previously described for carotid plaque tissue in Paper I. Depending on the results 
from the ex vivo carotid tissue stimulation with the TLR7 ligand IMQ, in Paper II only the 
highest dose of IMQ was used in the ex vivo aortic valve culture.  
 
Figure 4. Ex vivo tissue stimulation assay. Human carotid plaque (Paper I) and tricuspid aortic valve tissue 
(Paper II) was cut into ~2mm2 pieces and distributed to 48 well plate. The tissue was stimulated with the TLR7 
ligand IMQ. After 20h supernatant was collected and cytokine measurements were performed.   
The ex vivo assay can provide information on how diseased human tissues response to a ligand 
binding to TLR7, although there are several parts to consider. One consideration is the 
possibility the homogenizing procedure of the tissue to result in an uneven cell distribution in 
the different wells/conditions. The tissue was minced in small pieces and all parts were 
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thoroughly mixed before the distribution in the different conditions. Each condition was 
performed in duplicates. Furthermore, in our assay we cannot discriminate which cell subsets 
respond to ex vivo tissue stimulation with the TLR7 ligand. Cell isolation, sorting of the 
different cell populations and subsequent stimulation with a TLR7 ligand can provide 
additional information for the responding cells. However, this experimental approach comes 
with several disadvantages. Disassociation of immune cells and structural components from 
human carotid plaque and aortic valve requires strong enzymatic treatment that could  modulate 
the activation state of the cells and thus can alter the response.   In future set-ups more complex 
stimulation strategies could be used with testing of different TLR7 ligands and also combining 
with other mediators involved in atherosclerosis, eg oxLDL, TLR2 or TLR4 ligands. 
3.5 TRANSCRIPT ANALYSIS 
The most commonly used techniques for gene expression analysis are quantitative Polymerase 
Chain Reaction (qPCR), microarrays and RNA sequencing (RNAseq). In Paper I mRNA 
expression analysis of TLR7 in human carotid plaques was obtain from microarrays and qPCR. 
Microarrays, as previously discussed (above 1.4.1), offer the advantage of creating a transcript 
profile for a diseased tissue and thus providing information for the ongoing processes in the 
specific disease. However, microarrays demand robust normalization for comparison and 
background issues can occur for low expressing probes and similar sequences [194]. In Paper 
I and II microarray data were normalized with the Robust multi-array average method (RMA). 
This normalization is broadly used as a standardized method to normalize array data.  In Paper 
I microarray analysis identified an association of TLR7 mRNA expression that was validated 
with qPCR. qPCR offers high specificity and sensitivity. 
Technological advances have led to the discovery of newer methods such as RNAseq for 
transcript analysis. RNAseq has offered several advantages including the dynamic range, high 
resolution with detection of changes in a single base and accuracy [194]. However, the high 
cost and the generation of a big complex dataset have earlier created difficulties in data 
handling. Still microarrays are used to some extent in new projects since they offer lower cost 
and the established standardized analysis procedures facilitate the interpretation of the data but 
their usage will probably decrease.       
3.6 MOUSE MODELS OF ATHEROSCLEROSIS 
The most common mouse models used for the study of experimental atherosclerosis are  
Apoe-/- and Ldlr-/- mice. In Paper III we choose to use 22 weeks old female Apoe-/- mice.  
Apoe-/-  mice spontaneously develop atherosclerosis without the demand of additional high fat 
diet. We choose to use mice that have already advanced atherosclerotic lesions in order to have 
the same disease stage as in Paper I where our results were generated in late stage advanced 
human lesions. Furthermore, our group and others have shown that mice around 22 weeks old 
have established lesions.  In addition, the use of high fat diet was avoided due to possible effect 
on immune activation. Several members of the TLR family, such as TLR4 and TLR2 can be 
strongly activated by PAMPs present in high cholesterol atherogenic diets [195]. 
 26 
  
 27 
 
4 RESULTS AND DISCUSSION 
4.1 TLR7 EXPRESSION IN HUMAN CAROTID PLAQUE IS ASSOCIATED WITH 
FEWER ADVERSE CARDIO- AND CEREBROVASCULAR EVENTS 
In Paper I we investigate the role of TLR7 in human carotid advance atherosclerosis using 
data and samples included in our biobank of carotid endarterectomies, BiKE. Most of the 
studies exploring the role of TLR7 in atherosclerosis have been performed in animal models. 
The receptor has been previously connected with protective effect in an Apoe-/-xTlr7-/- mouse 
model [130]. The double deficient mice presented increased atherosclerosis, accompanied by 
accumulation of pro-inflammatory macrophages in plaques in the aortic root. In addition, 
mRNA levels of TLR7 were increased in the human atherosclerotic plaque compared to normal 
arteries and correlated with anti-inflammatory M2 macrophages in BiKE [130]. In our study, 
TLR7 mRNA levels in patients´ removed carotid plaque were divided in tertiles and analyzed 
for the re-occurrence of cardio- and cerebrovascular events. The cox regression analysis 
revealed that the patients in the highest and middle tertiles were associated with better outcome 
with fewer cardio and cerebrovascular events compared to the patients that expressed low 
TLR7 mRNA levels in their removed plaque (Figure 5). These data indicated that TLR7 could 
be involved in protective pathways that lead to stabilization of advanced carotid plaques. The 
association of high TLR7 mRNA levels with better outcome was validated by Real time (RT)-
PCR. In addition, in our analysis we adjusted for common cofounders in atherosclerosis; age, 
sex and LDL levels. Adjustment for these cofounders did not affect the outcome; however, 
there are other factors to be considered that could be addressed in larger cohorts.  
Other studies have associated mediators to cardiovascular disease outcome [196-198]. Our 
group has previously identified that high levels of adiponectin in the plasma of patients 
undergoing carotid endarterectomy were associated with all cause mortality [196]. In addition, 
increased expression of TLR2 and TLR4 in monocytes of patients admitted in the hospital with 
stroke were associated with worse outcome regarding neurological impairment [197, 198]. 
These studies were performed in material derived by blood. In our study, we associated the 
expression levels of a pattern recognition receptor in carotid atherosclerotic plaques with 
patients´ secondary cardiovascular events. Although, blood biomarkers are involved in disease 
pathogenesis, how well the microenvironment and the ongoing processes is reflected in blood 
is not clear. In Paper I we have identified TLR7 as part of possible protective pathways in 
atherosclerotic lesions.  
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Figure 5.  Better outcome was found for patients with higher levels of TLR 7 transcript in their removed 
carotid plaques. Kaplan–Meier curve illustrating MACCE-free survival of patients with TLR7 expression of 
highest tertile (black), the middle tertile (dark grey) and the lowest tertile (light grey). TLR7 mRNA levels were 
derived by microarray analysis of carotid plaques. Below the Kaplan Meier plot, the count of event-free patients 
is indicated. The x-axis indicates the time since CEA in months. In the upper-right corner is reported the Hazard 
ratio (HR) generated by Cox regression for the lowest tertile of TLR7 expression vs. the middle and highest tertiles 
combined [199]. 
In order to explore the expression of TLR7 in advanced atherosclerosis, human carotid plaques 
were co-stained for TLR7 and cellular markers. The double immunofluorescence staining 
revealed that infiltrated leukocytes but not carotid smooth muscle cells expressed the receptor. 
Specifically, both CD4+ and CD8+ T cells expressed TLR7 as well as FoxP3+ Tregs. CD4+ cells 
(TH subtypes) are mainly thought to be pro-atherogenic [200]. However, it has been shown that 
TLR7 activation can lead to anergy in human CD4+ T cells [201]. In addition, Tregs have been 
shown to be highly atheroprotective in several experimental studies by promoting resolution of 
inflammation [202]. The role of CD8+ T cells is not fully understood yet. A recent study has 
shown that depletion of CD8+ cells resulted in plaques with bigger necrotic cores and decreased 
collagen. In addition, skewing towards CD4+ T helper cell phenotype was observed. These data 
indicate that CD8+ T cells might control proatherogenic CD4+ T cells and increase plaque 
stability [203]. Another study has shown that CD8+ regulatory T cells control T follicular helper 
cells and the formation of germinal centers and thus limiting the progression of atherosclerosis 
[204]. In contrast, activation of the CD137 receptor, a member of the TNF family that is 
expressed on CD8+ T cells and endothelial cells, promoted the progression of atherosclerosis 
[205].  
Regarding plaque macrophages, TLR7 was co-expressed with the pan-macrophage marker 
CD68 and CD163 a marker expressed by M2 macrophage. M2 macrophages have been shown 
to promote resolution of inflammation and plaque regression [113, 206]. In our study, we have 
investigated the main immune cell types involved in the development of atherosclerosis. In 
addition to macrophages and T cells we have attempt to investigate the expression of TLR7 in 
dendritic cells in the plaque. However, due to technical challenges these data are not available. 
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Further understanding of the expression and role of TLR7 in human carotid plaques could be 
addressed in future studies.  
Staining with the endothelial cell marker von Willebrand factor (vWF) revealed differential 
expression for TLR7 in endothelial cells in the human carotid plaque. TLR7 staining was 
observed in capillary endothelium but not in lumen endothelial cells. Although, the mechanism 
for differential expression of TLR7 in plaque endothelial cells is not clear, expression in the 
newly formed capillaries could be attributed to the atherogenic environment.  
Thereafter, the responsiveness of TLR7 in the human atherosclerotic plaques was evaluated in 
an ex vivo tissue model using a synthetic TLR7 ligand. Stimulation with the TLR7 ligand 
imiquimod (IMQ) elicited cytokine secretion in the culture media. A total of 20 cytokines were 
screened. Interestingly, IL-10 was significantly increased in response to TLR7 stimulation 
(Figure 6). IL-10 has been shown to mediate several atheroprotective processes, such as 
dampening of pro-inflammatory responses and promoting cholesterol efflux [207]. Some 
cytokines connected to pro-inflammatory phenotypes were also significantly increased. TNF-
α is traditionally considered as a mediator that promotes inflammatory responses [208]. 
However, a recent study has connected TNF-α to cardioprotective effect in an experimental 
model of heart failure [209]. Notably, established pro-atherogenic cytokines such as IL-6 were 
not significantly affected upon stimulation with the TLR7 ligand (Supplemental material).  
Although the natural ligand for TLR7 in atherosclerosis have not been established yet, DAMPs 
derived from apoptotic and necrotic cells such as RNA and HMGB1 have been suggested to 
activate intracellular TLRs [210]. For the stimulation of TLR7 in the ex vivo carotid plaque 
culture model, the synthetic ligand IMQ was used. IMQ has been shown to specifically 
stimulate TLR7 without co-stimulation of other TLRs [211]. Moreover, this ligand is already 
approved for the treatment of basal cell carcinoma and genital warts in humans [212].  
To further identify which cells respond to TLR7 ligand, we stimulated in vitro CD4+ and CD8+ 
T cells and CD14+ monocytes isolated from PBMC of patients undergoing carotid 
endarterectomy with IMQ. The stimulated immune cells elicited a weaker cytokine response 
compared to the response generated by stimulation of carotid plaque tissue ex vivo. Immune 
cells isolated from blood do not have the same differentiation stage compared to the cells 
present in the plaques. In addition, the plaque microenvironment and cell interactions can affect 
the magnitude of the response.  Thus, to identify the cells that produce IL-10 upon stimulation 
with TLR7 ligand, we performed immunofluorescence staining following the ex vivo 
stimulation of carotid plaque tissue with IMQ. The staining showed that macrophages, T cells 
and smooth muscle cells produce IL-10 (Figure 6). It has been previously shown that all the 
above cell types have the capacity to produce Il-10 [213, 214]. Although we did not observe 
co-staining of TLR7 with the smooth muscle cell marker a-actin, smooth muscle cells were 
expressing IL-10. It has been suggested that smooth muscle cells have a basal level of IL-10 
production in the plaque [214]. In addition, expression of IL-10 from smooth muscle cells upon 
TLR7 stimulation might be the result of cell interactions.  
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Figure 6. Summary of Paper I. High expression of TLR7 in the removed carotid plaque was correlated with 
better outcome for the patient with fewer reoccurring MACCE. TLR7 was expressed in macrophages, T cells and 
capillary endothelial cells in the human carotid plaque. Addition of TLR7 ligand in ex vivo cultures of carotid 
plaque tissue elicited the secretion of IL-10, TNF-α and GM-CSF. Both macrophages and T cells upon stimulation 
of carotid plaque with a TLR7 ligand produced IL-10. In Paper I we suggest that activation of TLR7 with 
endogenous or exogenous ligand in the plaque would lead to immunomodulatory effects by macrophages and T 
cells and eventually to a more stable plaque phenotype. Stabilization of the plaque would protect patients with 
high TLR7 expression in their lesions from future myocardial infarction or stroke. The schematic art pieces used 
in this figure were provided by Servier Medical art (https://smart.servier.com/). Servier Medical Art by Servier is 
licensed under a Creative Commons Attribution 3.0 Unported License. 
4.2 ASSOCIATION OF TLR7 EXPRESSION WITH ANTI-INFLAMMATORY 
MACROPHAGE SUBTYPE IN AORTIC VALVE STENOSIS  
 In Paper II we explore the expression and role of TLR7 in calcific aortic valve stenosis 
(CAVS). CAVS shares some risk factors and mechanisms of pathogenesis with atherosclerosis. 
In Paper I we have associated TLR7 with protection against atherosclerosis. Thus, we were 
interested to explore whether TLR7 is associated with similar effects in CAVS. Macrophages 
are present in atherosclerotic plaques and calcified aortic valves [99, 215]. In addition, 
macrophages have shown to be involved in all stages of atherosclerosis [215]. Hence, in Paper 
II we focus on expression of TLR7 in the different macrophage subsets in CAVS. In order to 
shed more light on the role of TLR7 in macrophage subtypes in CAVS, human calcified aortic 
valve samples and microarray data were obtained. The valves were macroscopically divided in 
a healthy, intermediate and calcified part, representing different stages of the disease (Figure 
7a).  
Transcript analysis revealed that the expression level of TLR7 was significantly increased in 
the calcified part of the aortic valve compared to the healthy and intermediate parts of the valve. 
The role of TLRs has been addressed mainly in VICs, where TLR7 expression was low to 
absent compared to TLR2 and TLR4 [125, 216]. In CAVS the research has been primarily 
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focused on VIC calcification processes. VICs are the most abundant cell type in the valve. 
However, immune cells, such as macrophages, T and B cells infiltrate aortic valves [99].  In 
contrast to other published studies, in our approach we include both infiltrating leukocytes and 
VICs.  
In order to investigate which macrophage subtype express TLR7, we correlated TLR7 mRNA 
levels with a set of macrophage markers associated with either M1 and M2 macrophages in the 
calcified aortic valves. TLR7 mRNA levels were significantly correlated with M2 macrophage 
subset genes in all parts of the valve (Figure 7b). Highest correlation was detected between 
TLR7 and the scavenger receptors MSR1, CD206 and CD163. No correlation with M1 
macrophage subset genes or vimentin (VIM) expressed by VICs, was observed. Co-expression 
of TLR7 with M2 macrophage markers was validated by double immunofluorescence staining 
of TLR7 and two of the high correlated M2 macrophage markers CD163 and CD206. A recent 
study indicated that M1 macrophages were increased in calcified compared to non calcified 
aortic valves, while M2 macrophage subtype presented the opposite trend. These data in 
combination with in vitro transfer of conditioned media from M1 macrophage to VIC, suggest 
that M1 macrophage promote calcification processes through secretion of pro-inflammatory 
cytokines [118]. As previously described, M2 macrophages have been associated with 
resolution of inflammation and tissue healing [217]. TLR7 was associated with scavenger 
receptors expressed by M2 macrophages, which could indicate capacity to clear apoptotic cells.  
Further studies are needed to show whether TLR7 is active in this process of clearance of 
apoptotic cells and calcification nodules. 
 
Figure 7. Association of TLR7 with M2 macrophage markers in calcified aortic valves. a) Image of calcified 
tricuspid valve. The circled areas indicate the different parts of the valve. b) Correlation of TLR7 mRNA levels 
with M2 macrophage markers in the healthy, intermediate and calcified part of the aortic valves. The red squares 
are highlighting the markers that were used to validate co-expression of TLR7 with M2 macrophages by double 
immunofluorescence staining.  
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In Paper II, we focused on the expression of TLR7 in macrophages in CAVS. However, it has 
been shown that human calcified aortic valves are infiltrated by other leukocytes such as T and 
B cells [218]. The expression and role of TLR7 in other immune cells could be addressed in 
future studies.   
Similarly, to Paper I we investigated the ability of human calcified aortic valve to respond by 
stimulating ex vivo with the TLR7 ligand IMQ. The dose of IMQ used in this study and the 
selection of measured cytokines in the culture media was based on our results in Paper I. 
Stimulation of aortic valve tissue with IMQ increased significantly the secretion of IL-10, TNF-
α and GM-CSF in the culture media. The effect of IL-10 in calcific aortic valves has not been 
studied yet. The proposed beneficial effects are supported by studies performed in 
atherosclerosis and other inflammatory diseases. TNF-α increased calcification in VIC derived 
from human calcified aortic valves in an in vitro calcification assay [219]. However, as it was 
previously discussed TNF-α have been connected to atheroprotection in another cardiovascular 
disease. Fine-tuning of the amount of TNF-α could lead to beneficial effects in cardiovascular 
disease.  
The ex vivo aortic valve tissue model provided information for the secretion of selected 
mediators in the culture media, yet we could not identify the responding cell types. In order to 
discriminate which cells respond to stimulation with TLR7 ligand, primary macrophages 
derived from blood monocytes and VICs extracted from calcified aortic valves were stimulated 
with IMQ. Upon stimulation with TLR7 ligand macrophages significantly increased the 
secretion of IL-10 while no change was observed in VICs. Unresponsiveness of VICs to 
stimulation with a TLR7 ligand was previously shown in vitro.  In addition, TNF-α was 
undetectable in VICs. These results indicate that the main producer of IL-10 and TNF-α in 
calcified aortic valves are the macrophages. In another study, immunofluorescence staining in 
human calcific aortic valve reveal co-expression of TNF-α with the macrophage marker CD68 
[220]. Nevertheless, response to TLR7 ligand by other immune cells cannot be excluded.  
In our study, we investigate the expression and role of TLR7 activation mainly in macrophages. 
However, we did not assess the effects of TLR7 activation in calcification, the hallmark of 
calcific aortic valve stenosis [218]. VICs seem to not respond or being low responders upon in 
vitro stimulation with a TLR7 ligand, in contrast to macrophages. Experiments such as 
conditioned media transfer from macrophages stimulated with TLR7 ligand to VICs or co-
culture systems of macrophages and VICs in the presence of a TLR7 ligand would provide 
more insight on calcification processes.    
4.3 IN VIVO TREATMENT WITH A TLR7 LIGAND INDUCED PROTECTIVE 
RESPONSES IN SPLEEN AND DECREASED EXPERIMENTAL 
ATHEROSCLEROSIS  
Paper III investigates the in vivo effects upon activation of TLR7 in experimental 
atherosclerosis, connecting to the two studies in biobanks. We were interested to evaluate both 
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local and system effects of the treatment. The primary focus of the study was the effect of 
treatment with a TLR7 ligand on atherosclerotic lesion burden. In order to investigate the 
effects of the treatment in atherosclerotic lesions, we treated atherosclerotic mice with 
established lesions. Several studies and experience with the mouse model in the group indicate 
that mice in the age of 20 weeks present complex atherosclerotic lesions that are still 
progressing. The age selection of the mice at the initiation of the treatment was chosen to 
connect to our results in Paper I, where we investigated the role of TLR7 in advanced 
atherosclerotic plaques.  
Our treatment of 22 weeks old Apoe-/- mice with a TLR7 ligand resulted in decreased 
atherosclerotic burden compared to control group injected with PBS. Between treated mice and  
a baseline group that was euthanized at the initiation of the treatment, we detected a tendency 
towards smaller lesions, however the change was not statistically signinficant. These data 
indicate that stimulation with TLR7 ligand activated atheroprotective processes that arrested 
lesion progression.  
In parallel to our study, another study has been published were treatment with the same TLR7 
agonist we used resulted to increased atherosclerosis [134]. The two studies have several 
differences in experimental design that might explain the different results. We treated 22 week 
old mice with established lesions while Krogmann et al started the treatment of mice at 10 
weeks. In addition, the route of injection was different; we performed intraperitoneal while the 
other group did intravenous injections. Last, as it was previously discussed, in order to avoid 
cross activation of other TLRs that can affect the disease outcome we used normal diet in 
contrast to the cholesterol-rich diet used in the other study [134]. Further studies are needed to 
explore the different effect of TLR7 ligands in atherosclerosis models. 
In Paper I and II we used the TLR7 ligand IMQ challenging human tissue, while in Paper 
III we used R848. Since R848 has been used in several experimental mouse studies for the 
activation of TLR7 [221, 222] with clear results we chose to use this ligand. R848 is a ligand 
that can activate both TLR7 and TLR8 in human cells. Early data has showed that TLR8 is not 
functional in mice, only in humans [223, 224]. In the KO model of TLR7, the R848 ligand did 
not elicit any response in spleen cells, a compartment for all leukocytes. A recent study has 
however showed that TLR8 is active in neuronal tissue of mice [225].   
We were interested to investigate systemic effects of TLR7 stimulation in atherosclerotic mice. 
Previous studies by our group and others have shown an important role for the spleen in the 
outcome of atherosclerosis [159, 173]. In addition, at time of sacrifice we observed increase in 
spleen size of the treated mice. We therefore explored changes in the main immune populations 
in the spleen such as B and T cell subsets. Our analysis revealed an increase of MZ B cells and 
Tregs (Figure 9). Several studies have shown that MZ B cells and Tregs are atheroprotective 
[149, 162].  
In our study, we show expansion of Tregs and MZ B cells in the spleen of treated mice with 
the TLR7 ligand. However, we did not investigate all steps of TLR7 activation in the respective 
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cell types. We cannot distinguish whether TLR7 acts directly on Tregs and MZ B cells, or 
whether the observed effect is the result of cell interactions in the spleen. Previous studies have  
shown that TLR7 is expressed by both Tregs and MZ B cells [226, 227]. In addition, both cell 
types have been described to respond to TLR7 ligands in vitro [227, 228]. Stimulation of Tregs 
with a TLR7 ligand enhanced their ability to control the proliferation of CD4+CD25- T cells 
and inhibited the secretion of pro-inflammatory cytokines [228].  Furthermore, MZ B cells 
stimulated in vitro with R848, were differentiated in plasma cells and produced IgM antibodies 
[227]. The above studies have shown direct effect of TLR7 in Tregs and MZ B cells. In 
addition, protective effects of treatment with a TLR7 ligand through interaction between B 
cells and Tregs have been described. Induction of Tregs as response to stimulation with the 
TLR7 ligand R848 reduced asthma symptoms in an experimental mouse model in a B cell 
dependent manner [222].  
The main effector function of B cells is the production of antibodies. Since we have observed 
a two-fold increase of MZ B cells in the spleen, we were interested to investigate changes in 
antibody levels in circulation. Measurements of IgM and IgG antibodies in the plasma of TLR7 
ligand treated mice revealed a significant increase in IgM antibodies. IgM antibodies are 
polyreactive antibodies secreted by MZ B and B1 cells that bind conserved epitopes through 
molecular mimicry, such as apoptotic cells and oxLDL epitopes [74]. Several studies have 
shown that IgM antibodies against oxLDL convey atheroprotection [179, 229]. 
 
Figure 8. Time course treatment with TLR7 ligand showing inverse trend of cholesterol levels and anti-
oxLDL IgM antibodies. a) Schematic representation of the treatment of Apoe-/- mice with the TLR7 ligand R848. 
Blood was collected 24h after injection with R848 or PBS. b) Graph depicting cholesterol and anti-oxLDL 
antibody levels of PBS and R848 injected mice. Cholesterol levels drop significantly after the fourth injection 
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when we observe significant increase in anti-oxLDL IgM antibody titers. Red lines represent the R848 group and 
black lines PBS group. Solid lines represent cholesterol levels and dotted lines anti-oxLDL IgM antibodies [230].  
MZ B cells and IgM antibodies against LDL oxidation epitopes play important role for the 
protection against atherosclerosis. Injection of apoptotic cells to Apoe-/- mice decreased 
cholesterol levels through increase of anti-PC antibodies and expansion of MZ B and B1a cells 
[160]. We have also observed increased levels of anti-oxLDL IgM antibodies upon treatment 
with a TLR7 ligand.  Furthermore, our treated mice presented decrease in plasma cholesterol 
levels. Taken together, these data indicate that the decrease in cholesterol levels could be 
related to an increase in anti-oxLDL antibodies in circulation. More evidence has been added 
in this line by our time course experiment where we treated mice with TLR7 ligand and 
obtained blood sample after each injection (Figure 8a). Measurement of anti-oxLDL IgM 
antibodies and cholesterol levels indicated that the increase in antibodies preceded the decrease 
in cholesterol levels (Figure 8b). However, we cannot exclude activation of metabolic 
pathways upon stimulation with a TLR7 ligand. A study of non-alcoholic fatty liver disease 
(NAFL) revealed that cholesterol accumulation was decreased in the liver of experimental 
animals through TRL7 induced autophagy. Future studies are necessary to clarify the role of 
TLR7 in decrease of cholesterol levels [231].    
In addition to the systemic effects that were described above, IgM antibodies against oxLDL 
have been proven to have local atheroprotective effects [173, 175]. There are two suggested 
mechanisms by which IgM against modified epitopes of LDL exert protective role in 
atherosclerosis. First, studies have shown that anti-oxLDL IgM antibodies decrease the uptake 
of oxLDL by macrophages in atherosclerotic lesions [175, 176]. Second, anti-oxLDL 
antibodies bind to apoptotic cells through molecular mimicry and enhance efferocytosis [232].  
Increased foam cell formation and cell death in combination with defective efferocytosis leads 
to generation of larger necrotic core, one of the characteristics of unstable plaques. We have 
observed infiltration of IgM antibodies in the plaque of TLR7 ligand treated mice compared to 
PBS. Staining of the lesions, revealed that treated mice with TLR7 ligand had smaller necrotic 
core, which was accompanied with fewer apoptotic cells in the lesions. However, in our study 
we cannot prove whether the decrease in apoptotic cells is due to enhancement of efferocytosis 
versus promotion of survival signals.   
 36 
 
Figure 9. Summary of Paper III. In vivo treatment with the TLR7 ligand R848 reduced atherosclerotic lesion 
size in 22 week old Apoe-/- mice. The treatment led to systemic and local lesion effects. The systemic effects 
included expansion of MZ B cells and Tregs in the spleen. Furthermore, treatment with R848 reduced cholesterol 
levels and increased anti-oxLDL levels in the plasma of atherosclerotic mice. Locally, in the lesions increased 
accumulation of IgM antibodies was observed in the treated mice. Furthermore, the lesions presented decrease in 
necrotic core area and in apoptotic cell numbers. In Paper III we suggest that TLR7 induces anti-oxLDL IgM 
antibodies that decrease plasma cholesterol and reduce plaque size by blocking oxLDL uptake by macrophages 
and increasing efferocytosis in the plaques. Effective clearance of apoptotic cells would lead in smaller necrotic 
core and hence a more stable plaque [230]. The schematic art pieces used in this figure were provided by Servier 
Medical art (https://smart.servier.com/). Servier Medical Art by Servier is licensed under a Creative Commons 
Attribution 3.0 Unported License.   
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5 CONCLUDING REMARKS 
Despite the success in new treatments with focus on the lowering of cholesterol levels, 
cardiovascular diseases remain the main cause of death worldwide. This indicates that there is 
the need to address the ongoing inflammatory processes involved in the pathogenesis of 
cardiovascular disease. The current thesis is focusing on the role of the pattern recognition 
receptor TLR7 in atherosclerosis and aortic valve stenosis. The expression and stimulation of 
the receptor has been investigated both in human and in vivo in an experimental mouse set up.  
In Paper I TLR7 expression levels in the atherosclerotic lesion improved patients´ prognosis. 
The expression of the receptor was revealed and localized mainly in immune cell populations 
in human atherosclerotic plaques. In addition, stimulation of the plaque with a synthetic 
exogenous ligand demonstrated the ability of the tissue to react fast and elicit a robust cytokine 
response. Taken together TLR7 is associated with protective pathways in atherosclerosis. 
These data could open the possibility for the use of TLR7 expression as a prognostic marker 
for patients undergoing endarterectomy. Furthermore, activation of TLR7 could be explored as 
possible therapeutic strategy for the stabilization of atherosclerotic plaque. However, it should 
be considered that pattern recognition receptors are potent, fast responding receptors that 
excessive activation could lead to adverse effects. Careful fine-tuning of the degree of 
activation and the right disease time point is necessary.  
In Paper II expression of TLR7 was demonstrated in aortic valves. TLR7 was associated with 
M2 macrophage markers and shown to be expressed in M2 macrophages in human calcified 
aortic valves. In a similar approach to Paper I, in Paper II was shown that human aortic valves 
have the ability to respond to synthetic TLR7 ligand with a mixture of anti-inflammatory and 
pro-inflammatory cytokines. Macrophages are main responders to stimulation with TLR7 
ligand, with the capacity to secrete large amounts of the respective cytokines. In Paper II 
association of TLR7 with M2 macrophages in the aortic valve suggested involvement of the 
receptor in resolution and tissue repair pathways. Enhancement of these pathways, that are 
defective in pathological environment, would be beneficial in cardiovascular disease.  
In Paper III administration of a synthetic TLR7 ligand decreased experimental atherosclerosis. 
With the in vivo treatment approach, we shed light on the systemic and locally activated 
pathways that TLR7 could be involved. Stimulation of atherosclerotic mice with a synthetic 
TLR7 ligand led to expansion of MZ B and Tregs and enhanced the secretion of protective 
antibodies against atherosclerotic epitopes. The treatment reduced cholesterol levels showing 
a possible immunometabolic effect of TLR7. These antibodies act in circulation by lowering 
plasma cholesterol and promote a stable plaque phenotype by increasing efferocytosis. A more 
stable plaque phenotype was observed in the treated mice. Taken together, in Paper III we 
suggest that TLR7 activates several beneficial pathways in atherosclerosis.  
As a final conclusion, this thesis highlights the protective role of the pattern recognition 
receptor TLR7 in cardiovascular disease. Furthermore, TLR7 expression in adaptive immune 
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cells and expansion of adaptive immune cells upon in vivo stimulation with a synthetic ligand 
displayed the role of the receptor in bridging innate and adaptive immune responses.  
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